Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2Adult Trial for the Treatment of Rett Syndrome

Yesterday, Taysha Gene Therapies announced that a 2^nd adult patient has been dosed with TSHA-102 in their gene therapy trial in Canada.  

Here are the key takeaways: 

• Taysha plan to share available clinical data (how the patients are doing) from the first two adult patients who have received the gene therapy in mid November, once the Independent Data Monitoring Committee have reviewed. 

• The third adult patient is expected to be given the gene therapy in late 2023 which would potentially complete enrolment of the low-dose group.  

• For clarity, the protocol as it stands says that the first three patients will receive a lower dose. All being well, the dose could be increased for subsequent patients. 

• The first child will be dosed with TSHA-102 in the US paediatric clinical trial in the first quarter of 2024. 

Here is a link to the full press release. 

Link to update re Patient #1 from August 2023 here

The community letter from Taysha is below